Halaven receives Israeli reimbursement

The advanced breast cancer drug Halaven (eribulin) has secured funding from health officials in Israel where one in eight women are affected by the disease.

Halaven is used to treat women with locally advanced or metastatic breast cancer who have progressed after at least one prior chemotherapeutic regimen for advanced disease.

The reimbursement agreement will benefit triple-negative breast cancer sufferers whose prior therapy should have included an anthracycline and a taxane, unless the patients were not suitable for these treatments.